FORM 6-K
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August 2004
Commission File Number: 1-14836
ALSTOM
------
(Translation of registrant's name into English)
25, avenue Kléber, 75116 Paris, France
--------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the Registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F X Form 40-F
----- -----
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes No X
----- -----
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes No X
----- -----
Indicate by check mark whether the Registrant, by furnishing the information
contained in this Form, is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes No X
----- -----
If "Yes" is marked, indicate below the file number assigned to the Registrant in
connection with Rule 12g3-2(b)
Enclosures:
Press release dated August 10, 2004, "ALSTOM's ADR Listing on NYSE"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ALSTOM
Date: August 11, 2004 By: /s/ Philippe Jaffré
-------------------------------------
Name: Philippe Jaffré
Title: Chief Financial Officer
10 August 2004
ALSTOM'S ADR LISTING ON NYSE
ALSTOM ordinary shares currently are listed on the Paris Stock Exchange and
American Depositary Receipts (ADRs) representing approximately 30 million ALSTOM
ordinary shares currently are listed on the New York Stock Exchange. The Company
delisted its UK Depository Receipts from the London Stock Exchange in November
2003.
The trading price of ALSTOM's ADRs has recently fallen below the minimum of $1
per ADR required in order to maintain the listing of the ADRs on the NYSE. The
volume of ADR transactions is very low (approximately 1% of the overall trading
in ALSTOM shares during the last six months). Therefore, after discussion with
the NYSE, ALSTOM has decided not to take steps, such as to modify its current
1:1 ADR/ordinary shares exchange ratio, as would be required to return to
compliance with the NYSE's continued listing criteria. ALSTOM expects that this
will lead to suspension of trading of the ADRs on the NYSE.
ALSTOM will determine in the near future whether its ADR program will be
continued. Should a decision be made to terminate the program, notice of the
termination date would be mailed to the registered owners of the ADRs at least
30 days in advance. Following any such termination, the ADR owners would
continue to be entitled for a period of one year to surrender their ADRs for the
underlying ALSTOM ordinary shares in accordance with the Deposit Agreement, but
would cease to be entitled to register transfers of the ADRs themselves.
ALSTOM will remain subject to SEC reporting requirements upon delisting.
Press enquiries: S. Gagneraud
(Tel. +33 1 47 55 25 87)
internet.press@chq.alstom.com
Investor relations: E. Châtelain
(Tel. +33 1 47 55 25 33)
investor.relations@chq.alstom.com